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Summary. We investigated the sources of MDR-TB in patients with isoniazid-resistant tuberculosis treated 
with 1st line anti-tuberculosis therapy and show that re-infection with a new MDR-TB strain was just as 
common as the emergence of rifampicin resistance among these patients.  
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ABSTRACT 
 
Background. Meta-analysis of patients with isoniazid-resistant tuberculosis given standard first-line anti-
tuberculosis treatment indicated an increased risk of multi-drug resistant tuberculosis (MDR-TB) emerging 
(8%), compared to drug-sensitive tuberculosis (0.3%). Here we use whole genome sequencing (WGS) to 
investigate whether treatment of patients with pre-existing isoniazid resistant disease with first-line anti-
tuberculosis therapy risks selecting for rifampicin resistance, and hence MDR-TB.  
 
Methods. Patients with isoniazid-resistant pulmonary TB were recruited and followed up for 24 months. Drug-
susceptibility testing was performed by Microscopic observation drug-susceptibility assay (MODS), 
Mycobacterial Growth Indicator Tube (MGIT) and by WGS on isolates at first presentation and in the case of 
re-presentation. Where MDR-TB was diagnosed, WGS was used to determine the genomic relatedness between 
initial and subsequent isolates. De novo emergence of MDR-TB was assumed where the genomic distance was 
five or fewer single nucleotide polymorphisms (SNPs) whereas reinfection with a different MDR-TB strain was 
assumed where the distance was 10 or more SNPs.  
 
Results. 239 patients with isoniazid-resistant pulmonary tuberculosis were recruited. Fourteen (14/239, 5.9%) 
patients were diagnosed with a second episode of tuberculosis that was multi-drug resistant. Six (6/239, 2.5%) 
were identified as having evolved MDR-TB de novo and six as having been re-infected with a different strain. In 
two cases the genomic distance was between 5-10 SNPs and therefore indeterminate.  
 
Conclusions. In isoniazid-resistant TB, de novo emergence and reinfection of MDR-TB strains equally 
contributed to MDR development. Early diagnosis and optimal treatment of isoniazid resistant TB are urgently 
needed to avert the de novo emergence of MDR-TB during treatment. 
 
Keywords. Tuberculosis; multidrug-resistance; isoniazid-resistance; whole-genome sequencing; rifampicin-
resistance. 
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Tuberculosis (TB), caused by Mycobacterium tuberculosis, kills more people each year than any other single 
pathogen [1].  Resistance to first-line anti-TB drug isoniazid is the most common drug resistant TB, with a 
global prevalence of 10%, and it is associated with increased risk of treatment failure and emergence of MDR-
TB with standard first-line TB therapy (11% and 8% respectively) compared to susceptible-TB (1% and 0.3% 
respectively) [2,3].  Emergence of multi-drug resistant TB (MDR-TB) strains, resistant to both isoniazid and 
rifampicin, is a major concern with an estimated 600,000 cases of MDR-TB or rifampicin-resistant TB each 
year [4]. MDR-TB requires longer treatment with more expensive and less effective antibiotics [5]. It is also the 
precursor for extensively drug-resistant TB (XDR-TB) [6]. Worldwide prevalence of MDR-TB among patients 
newly diagnosed with TB is approximately 3.4% compared to 18% among patients diagnosed for a subsequent 
time [1]. Treatment success remains low at about 56% [1]. Vietnam, where this study is set, has been one among 
the top 20 high TB and MDR-TB burden country in absolute number [1,7].  
MDR-TB strains isolated from patients initially with susceptible strains have in some past studies been ascribed 
to reinfection with a MDR-TB strain [8,9]. However, recent data suggest de novo emergence of MDR-TB may 
be playing a more significant role than previously thought. An analysis of a global data set of M. tuberculosis 
genomes found that isoniazid resistance typically emerges before rifampicin resistance [10], whilst a recent 
meta-analysis concluded that the treatment of patients with isoniazid-resistant disease with standard first-line 
drugs risks the emergence of MDR-TB [3]. WGS can be used to distinguish between de novo emergence and 
reinfection of MDR-TB and can provide genomic evidence to assess the source of MDR-TB [11-13]. 
A recently published study from Vietnam explored the bacterial risk factors for treatment failure among patients 
with isoniazid-resistant tuberculosis [2]. However that study did not explore whether patients who re-presented 
with MDR-TB had been reinfected with new strains or whether the original TB strain had evolved resistance de 
novo. Here we whole genome sequenced the longitudinally collected isolates from that study to test the 
hypothesis that standard first-line treatment of patients with isoniazid-resistant TB risks de novo selection for 
rifampicin-resistant mutations. 
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METHODS 
Ethical approval 
The study was approved by the Oxford University Tropical Research Ethics Committee, UK (OxTREC 030-07) 
and the Institutional Research Board of Pham Ngoc Thach Hospital in Ho Chi Minh city, Vietnam. All 
participants provided written informed consent.  
Patient recruitment 
Between December 2008 and June 2011, newly diagnosed patients with smear positive pulmonary TB were 
recruited in Ho Chi Minh City, Vietnam for a clinical study investigating the bacterial risk factors for treatment 
failure among patients with isoniazid-resistant TB [2]. Recruitment was restricted to new adult patients (aged 
>18) without HIV infection and no prior TB treatment [2]. Initial screening for isoniazid resistance was done 
using MODS [14] with results later confirmed using MGIT [2]. Follow-up was for 24 months with sputum 
collected, where this could be produced at 0, 1, 2, 5, 8, 12, 18 and 24 months after diagnosis. The patients were 
treated by Directly Observed Treatment, Short Course (DOTS) with the then standard first-line regimens 
according to the Vietnamese Ministry of Health guidelines for susceptible including isoniazid-resistant TB, two 
months of isoniazid, rifampicin, pyrazinamide and ethambutol followed by six months of isoniazid and 
ethambutol (2HRZE/6HE) or two months of isoniazid, rifampicin, pyrazinamide and streptomycin followed by 
six months of isoniazid and ethambutol (2HRZS/6HE) or other individualized treatment regimens 
(Supplementary Table 1) [2, 15]. 
Culturing M. tuberculosis isolates and Drug Susceptibility Testing 
Sputum samples from the patients were used to culture the M. tuberculosis isolates in the Pham Ngoc Thach 
hospital as per the protocol developed from national TB control programme, Vietnam (Supplementary methods).  
DNA extraction and whole genome sequencing 
M. tuberculosis isolates DNA were extracted using cetyltrimethylammonium bromide method [16]. This 
genomic DNA was used for library preparation using the Nextera XT kit (Illumina) and 150bp or 300bp paired 
end sequencing using MiSeq V2 or V3 reagent kits (Illumina) on the MiSeq sequencing platform (Illumina).  
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Whole genome sequence analysis 
FASTQ data generated on the Illumina MiSeq machine were mapped against the H37Rv reference genome 
(NC_000962.3) using bwa mem [17], SNPs were called using GATK (version 3.8-1-0-gf15c1c3ef) in unified 
genotyper mode [18]. These steps were carried out using the PHEnix pipeline (https://github.com/phe-
bioinformatics/PHEnix) and SnapperDB [19]. Maximum likelihood phylogenetic analysis was performed by IQ-
TREE v1.6 [20]. M. tuberculosis lineages, sub lineages and genotypic antibiotic resistance were identified by 
Mykrobe predictor TB platform [21].  
Genetic relatedness analysis 
Genetic relatedness between the M. tuberculosis isolates were analysed by constructing a phylogenetic tree of 
all the longitudinal isolates with WGS data (n = 368). Phylogenetic location and the SNP distance between the 
baseline and the MDR-TB isolates emerging in each patient were calculated. From base substitution rate of 0.3-
0.5 mutations/per genome/per year in M. tuberculosis isolates, SNP difference between the longitudinal isolates 
from our study and from the published literature [11,12,22], we used equal or less than five SNPs difference as a 
cut-off for the de novo emergence of MDR-TB from the initial isolate and more than ten SNP differences as 
reinfection with MDR-TB. SNP differences between 5 and 10 were described as indeterminate as it was difficult 
to differentiate either as de novo emergence or reinfection with another strain.  
RESULTS 
Characteristics of participants in the study 
2090 consecutively sampled patients were assessed for entry into the study, 1804 patients samples were culture-
positive and provided TB strains (Figure 1) [2]. 392 patients had TB strains with isoniazid resistance on MODS; 
50 patients declined to be followed up over 24 months and their results were excluded, 68 patients had MDR-TB 
and 274 had isolates with resistance to isoniazid and susceptibility to rifampicin. Of these 274, confirmatory 
phenotypic susceptibility testing by MGIT corroborated the isoniazid resistant result by MODS in 239 cases but 
reported susceptibility in 35 cases (Figure 1).  
Of those patients whose strains were isoniazid-resistant by both MODS and MGIT, 105/239 (43.9%) patients 
produced at least one more sputum samples, which were culture-positive over the 24 months follow-up, whereas 
134 (56.1%) patients had early sputum conversion as their subsequent sputum samples were culture-negative. 
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Of those patient strains whose MGIT result was susceptible for isoniazid, despite resistance reported by MODS, 
15/35 (42.8%) produced subsequent sputum samples which were culture-positive and experienced treatment 
failure and remaining 20 patients subsequent sputum samples were culture-negative. Similarly, only 43/68 
MDR-TB patients had subsequent sputum samples which were culture positive and for remaining 25 MDR-TB 
patients subsequent M. tuberculosis isolates were unavailable. Treatment data for 134 patients with early sputum 
clearance and 50 patients who declined to participate showed six having unfavorable and rest favorable 
outcome.   
MDR-TB was detected by MGIT during 24 months follow-up in subsequent isolates from 18/105 patients 
whose baseline isolate was isoniazid-resistant by both MODS and MGIT, and 5/35 patients with baseline 
isoniazid-susceptible isolates by MGIT, discordant with MODS result. For 3/18 patients with emergence of 
MDR-TB, the initial isolate was phenotypic rifampicin susceptible by MGIT but WGS detected rifampicin-
resistant mutations and WGS data was lacking for isolate from 1/18 patient. These four patients were excluded 
from analysis (Figure 1). For 163 patients with strains having WGS data, Median age was 41 years, 74.2% were 
male and 50.6% reported smoking (Supplementary Table 1).  
Temporal dynamics of emergence of MDR-TB in patients  
Of the 14 patients who initially had an isoniazid resistant strain and developed MDR-TB, 11 did so within the 
first five months of treatment whereas three were diagnosed with MDR-TB 12 or 24 months after completing 
initial treatment. Of the five patients who developed MDR-TB with baseline susceptible strain by MGIT, four 
did so within five months of starting treatment and one was diagnosed with MDR-TB at 12 months (Figure 2). 
161/162 patients received only two or three months of rifampicin during the intensive phase, whilst 1/162 
patient received rifampicin for six months during the treatment (Figure 2, Supplementary Table 1). 
Genetic relatedness between the initial and the first MDR-TB isolate in the same patients 
To help assess genomic links between isolates and potentially explain MDR-TB acquisition, all longitudinally 
collected whole genome sequenced isolates were assessed for genomic relatedness (n=368 isolates) (Figure 1). 
In 6 (43%) out of 14 patients with initial isoniazid-resistant disease, the subsequent MDR-TB isolates were 
within five SNPs of their original isolates, and not closely related to any other sequenced strains, indicating de 
novo emergence (Figure 3A, B and Supplementary Table 2). One patient appeared to have no SNPs separating 
the initial isoniazid-resistant and subsequent MDR-TB isolate. However, on closer inspection a mixed-call was 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa254/5804256 by guest on 17 M
arch 2020
 8 
 
detected in rpoB at codon 445 with a His to Tyr substitution accounting for 70% of sequencing reads, below the 
90% cut-off used for SNP calling (Table 1, Pt080). In two cases SNP difference between the initial isoniazid-
resistant and the MDR-TB isolates were six and seven SNPs respectively, thus not clearly distinguishing de 
novo acquisition from reinfection. In the remaining four patients the initial isoniazid-resistant and MDR-TB 
isolates were separated by 19, 43, 896 and 1036 SNPs respectively, indicating reinfection (Figure 3A, B and 
Supplementary Table 2), whilst for two patients WGS indicated a mixture of strains in their second clinical 
isolate, with at least one of the strains in each mixture being MDR. The initial isoniazid-resistant isolate was not 
present at the later time-point in either sample. Six of 14 patients were therefore deemed to have been reinfected 
with MDR-TB (43%).  
Of the five patients who initially had susceptible disease and were later diagnosed with MDR-TB, SNP 
distances between paired isolates ranged from 69 to 1077, indicating reinfection in each instance. Overall, we 
therefore found that MDR-TB emerged de novo in 6/239 (2.5%) patients who were diagnosed with isoniazid-
resistant TB by MODS and MGIT, and in 0/35 patients whose strains initially tested isoniazid-resistant by 
MODS only (Figure 3A, B and Supplementary Table 2). 
 
De novo emergence or selection of M. tuberculosis variant with rifampicin resistant mutations during the 
emergence of MDR-TB  
For 5/6 patients with de novo emergence of MDR-TB, mutations known to confer resistance to isoniazid (katG 
S315T (in 4/6 cases, 66.66%) and fabG1 C-15T (in 1/6 case, 16.66%)) and to streptomycin (rpsL K43R and 
K88R) were detected in the original isolates (Table 1). In the remaining patient, the isoniazid and streptomycin 
phenotypic resistant isolate had pre-existing known pyrazinamide-resistant mutations in the genes rpsA and 
pncA, but lacked any known isoniazid or streptomycin resistant mutations, so was probably a resistant 
phenotype linked to unknown genetic variants. One patient also had an embB mutation at the outset, although 
the ethambutol phenotype was susceptible (Pt072, Table 1). In 155 patients without emergence of MDR-TB, 
111 had katG S315T (71.61%), 6 had fabG1 C-15T (3.87%) and rest lacked any known isoniazid-resistant 
mutations. No significant difference of these mutation frequencies from the strains in which de novo MDR-TB 
emerged (p = 0.25, Fisher’s exact test). In each of the six de novo MDR-TB cases, known rifampicin-resistant 
mutations emerged in subsequent isolates (S450L, H445Y and D435V) (Table 1). The proportion of sequencing 
reads containing either the relevant rpoB mutation or wildtype could be assessed at different time intervals in the 
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six patients. One month into treatment the resistant allele accounted for as few as 10% of reads in one patient 
and for over 90% of reads in another patient’s isolate, although in the former case the phenotype did not convert 
to ‘resistant’ until the number of resistant alleles had grown further to 90% at 12 months  (Table 1). For four 
patients the resistant rpoB allele accounted for between 66% – 76% of reads by eight months, below the 90% 
cut-off used for the variant calling, but sufficient to impact the phenotype and be detected by Mykrobe analysis 
(Table 1). The emergence of an embB mutation resulting in resistance to ethambutol could also be observed in 
one case (Pt108) after eight months of treatment (Table 1A).  Three other non-synonymous mutations also 
emerged, in hypothetical protein Rv1444c (M109V) and Rv3806c/ubiA (I162L) in Pt078 and hypothetical 
protein Rv2472 (C84R) in Pt102 (Table 1). ubiA has previously been linked to ethambutol resistance, although 
it did not result in a phenotypic change on this occasion [23].   
For the two patients with intermediate SNP distances between their first and subsequent isolates, known 
rifampicin-resistant mutations emerged, and in one case an ethambutol resistant mutation also emerged along 
with a corresponding resistant phenotype (Pt079). Two different rifampicin-resistant variants were observed in 
patient (Pt079) (Table 1). 
Out of eight patients with de novo MDR-TB emergence or an intermediate SNP distance between isolates, five 
received 2SHZR/6HE, two received 2RHZE/6HE and one received 2SRHZ/1RHZ/5HE as treatment regimens 
(Table 1).  
For 9/11 patients with MDR-TB reinfection but no mixed reads in their MDR-TB isolates, all reinfections were 
of lineage 2.2.1 with mutation in EsxW-Thr2Ala. This was the same lineage as the initial infection for five 
patients whereas the other four were initially infected with strains from lineages 1.1.1.1, 4.8, 4.1.2 and 4.5 
(Table 2). The overall prevalence of lineage 2.2.1 among MDR-TB isolates was 79% and 71% among isoniazid-
resistant and susceptible isolates. 
There were no instances where rifampicin-resistant alleles were detected in the initial M. tuberculosis isolates of 
either patients who later went on to evolve MDR-TB de novo or due to reinfection at sequencing depth of 30x. 
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DISCUSSION 
Here we provide genetic evidence for the de novo emergence of MDR-TB among patients treated with first-line 
drugs for isoniazid-resistant TB. Contrary to previous studies that found MDR-TB to be the consequence of 
reinfection [8, 9], de novo emergence of MDR-TB was equally common to reinfection with a separate MDR-TB 
strain among patients with pre-existing isoniazid-resistant TB.  
Our findings support the conclusions from recent studies indicating the risk of prior isoniazid resistance in the 
evolution of rifampicin resistance [3, 10]. We observed 6/239 (2.5%) patients with initial isoniazid-resistant TB 
acquiring MDR-TB de novo and 8/239 (3.3%) patients who were either reinfected with a new strain that was 
MDR, or for whom the results were indeterminate. There was no significant difference in clinical presentations 
between patients with and without emergence of MDR-TB except for drinking alcohol (Supplementary Table 3). 
The isolates from patients in Vietnam are not routinely screened for isoniazid-resistance [2]. This is also true for 
patients in many other low and middle-income countries. Rapid molecular diagnosis methods are available or 
under development to improve the detection of antibiotic-resistant TB such as Xpert MTB/RIF Ultra for 
rifampicin resistance and DNA line-probe assays such as the AID TB Resistance LPA and GenoType 
MTBDRplus VER2.0 for isoniazid and rifampicin resistance detection [24]. It is well understood that sub-
optimal antibiotic regimens can select for resistant mutations in the M. tuberculosis population [25]. All the six 
patients with de novo emergence of MDR-TB as well as the two patients with intermediate SNP distances 
separating their longitudinal isolates were already resistant to streptomycin as well as isoniazid. Two also had 
mutations conferring resistance to ethambutol leaving rifampicin almost entirely unprotected during the 
intensive phase, exposing it to selection pressure driving the emergence of rifampicin-resistant variants in the 
population.   
Although treatment regimens for isoniazid-resistant TB have changed to 2RHZE/4RHE since this study 
recruited, the emergence of rifampicin resistance during the intensive phase of treatment among our study 
patients is a major concern. In today’s regimens it is protected only by ethambutol in the continuation phase in 
patients with isoniazid resistance. Our findings clearly underscore the need for rapid, comprehensive DST 
testing and implementation of new World Health Organization guidelines for treating isoniazid-resistant TB 
with six months of rifampicin, ethambutol, pyrazinamide and levofloxacin [26].        
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TB endemic countries have a higher risk of mixed or reinfection [27]. Mixed infection is harder to diagnose and 
patients risk being treated with regimens that select for resistant bacterial populations [28]. Reinfection with 
MDR-TB is a major concern especially where hospitalization, visit to out-patient departments and DOTS clinic 
risks exposure to other TB patients [29].  
Standard culture based WGS on M. tuberculosis isolates cannot rule out the presence of minor-resistant alleles 
prior to treatment [30]. The early detection of emergence of MDR-TB minor-variants in the patient can help 
clinicians to appropriately change the treatment regimen [31].  
The Beijing sub-lineage 2.2.1 was responsible for each patient who was secondarily infected with MDR-TB, 
consistent with the high prevalence and observation that Beijing sub-lineage 2.2.1 is involved in enhanced 
transmission among the host population in Vietnam [32].        
There are some limitations in our study. Most importantly, we have only focused on the old eight-month TB 
treatment regimen that lacks rifampicin in the continuation phase. This was because the strains from a previous 
study were readily available to us to investigate this important question [2]. This may have decreased the 
frequency of de novo emergence of MDR-TB from isoniazid resistant TB, as there was no rifampicin selection 
pressure after initial two months of treatment. However, observing resistance emerge during the intensive phase 
when rifampicin is supposedly protected by more drugs than in the continuation phase is sobering. MTB/RIF 
Xpert remains the assay of choice in many low and middle-income settings but would no more pick up the 
resistance to ethambutol, pyrazinamide or second-line injectable drugs now than it would have then. The risks 
associated with incomplete diagnostics are therefore apparent.  A separate weakness is we cannot rule out the 
possibility of MDR-TB reinfection with an isolate that is related genetically to the initial isolate, for example 
from a household contact. We also lacked follow up data for the patients whose initial MODS screening result 
was isoniazid susceptible. This may have underestimated the de novo emergence of MDR-TB in patients with a 
susceptible M. tuberculosis isolate.  
In conclusion, our study found that de novo emergence of MDR-TB in patients with isoniazid-resistant TB 
occurred equally frequently to reinfection with MDR-TB in this cohort. It is not routine for drugs other than 
rifampicin to be screened for resistance at diagnosis. This study provides genetic evidence that such a narrow 
diagnostic focus risks selection for MDR-TB.   
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Figure legends  
Figure 1. Study flow diagram. 
 
Figure 2. Emergence of MDR-TB during treatment in patients. Mapping of phenotypic drug susceptibility 
testing of longitudinal M. tuberculosis isolates at different months (0M, 1M, 2M, 5M, 8M, 12M, 18M and 24M) 
during treatment or recurrence post-treatment from 101 patients initially with isoniazid-resistant TB and five 
patients with susceptible TB. MDR-TB emergence grouped at the bottom, confirmed based on phenotypic and 
genotypic DST. Color code indicates antibiotic susceptibility and no isolate (time points lacking positive M. 
tuberculosis cultures from the patients). 99 patients initially with isoniazid resistant TB had DST results for 
more than one isolate, whereas two patients had DST for only initial 0M isolate as later isolates failed to revive 
during sub-culture. 
 
Figure 3. Genetic distance between initial isoniazid-resistant (INH-R) or susceptible isolate and MDR-TB 
isolates. (A) Phylogenetic tree of longitudinal M. tuberculosis isolates.  Emergences of MDR-TB in the 
phylogenetic tree are indicated in the adjacent panel by patient code, location number in the phylogenetic tree 
and collection time points (in months). Patients are grouped based on SNPs difference between initial and 
MDR-TB isolates, equal or less than five SNPs (de novo), 6 to 10 SNPs (intermediate) and more than 10 SNPs 
(reinfection) of emergence of MDR-TB from patients initially with isoniazid or susceptible TB (color code 
indicates antibiotic susceptibility). Genetically related isolates from the same patient at different time points are 
indicated by blue bars in the phylogenetic tree at the respective location number and blue square highlighting the 
respective collection time points, genetically unrelated isolates at different time points from the same patient are 
indicated by red bars in the phylogenetic tree at respective location number. Location numbers for isolates from 
a patient follow the order of collection time point, related isolates from the same patient are given single 
location number. Outer ring around the phylogenetic tree indicates different M. tuberculosis lineages by color 
code. * Patient with 19 SNPs difference between initial isoniazid resistant and MDR-TB isolates, ** Patients 
with mixed infection removed from phylogenetic tree but analysed manually. (B) SNP distance or difference 
between the initial and the first MDR-TB isolate pair in patients initially with susceptible (SNPs range 69 - 
1077) or isoniazid resistant isolate (INH-R, SNPs range 1 to 1036). Note : one patient had zero SNP 
difference between the initial isoniazid resistant and MDR-TB isolate and that data point is not shown in 
the graph. Black line indicates five SNPs cut-off. 
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ID 
Preexisting 
antibiotic 
resistant 
mutations 
(WGS) 
Preexisting 
antibiotic 
resistant 
phenotype 
(MGIT) 
Antibiotic  resistant mutations 
emerged in MDR-TB 
(Month, % genetic variant ) 
Emerging 
antibiotic 
resistant 
phenotype 
(Month) 
Other mutations 
(Month,  
% genetic variant) 
M. tuberculosis 
sub-lineage 
Lineage 
specific 
SNP 
Treatment regimen 
Pt072 katG S315T 
rpsL K43R 
embB M306I 
INH 
STR 
rpoB H445Y 
(1M, 2M > 90%, 5M = 74%) 
RIF 
(1M, 2M, 5M)  
             2.2.1.1 
 
 
embB 
(D534D) 
2RHZE/6HE 
 
Pt078 rpsA V260I 
pncA C14R 
INH 
STR 
rpoB H445Y 
(5M = 66%, 8M > 90%) 
RIF 
(5M, 8M) 
Rv1444c (M109V): 
hypothetical protein, (5M 
= 62%, 8M > 90%) 
Rv3806c (I162L), ubiA* 
(8M > 90%) 
1.1 Rv3915 
(L352L) 
2SRHZ/RHZ/5HE 
 
Pt080 katG S315T 
rpsL K88R 
INH 
STR 
rpoB H445Y (8M = 70%) RIF 
(8M) 
 2.2.1 Rv0697 
(L268L) 
2SHRZ/6HE 
 
Pt102 katG S315T 
rpsL K43R 
INH 
STR 
rpoB S450L 
(1M =10%, 12M, 18M > 90%) 
RIF 
(12M, 18M) 
Rv2472 (C84R) 
Hypothetical protein, 
(0M = 73%, 12M, 18M 
>90%) 
2.2.1.1 embB 
(D534D) 
2RHZE/6HE 
 
Pt108 katG S315T 
rpsL K43R 
INH 
STR 
rpoB D435V 
(2M = 76%, 8M,12M, 
18M, 24M > 90%) 
embB M306V (8M,12M, 18M , 
24M >90%) 
RIF 
(2M, 8M, 12M, 
18M, 24M) 
EMB 
(8M, 12M) 
 2.2.1 Rv0697 
(L268L) 
2SRHZ/6HE 
 
Pt152 fabG1 C-15T 
rpsL K88R 
INH 
STR 
rpoB D435V (24M > 90%) RIF 
(24M) 
 4.5 Rv1524 
(P344P) 
2SHZR/6HE 
 
Patients with intermediate SNPs difference   
Pt061 katG S315T 
embB M306I 
rpsL K43R 
INH 
STR 
rpoB S450L (2M = 20%) RIF 
(2M) 
 
 
NADH 
pyrophosphatase 
nudC P239R (0M= 
80%, 2M >90%) 
2.2 Rv2231c 
(A205A) 
2SHRZ/6HE 
 
Pt079 
 
katG S315T 
rpsL K43R 
 
INH 
STR 
rpoB H445P (1M = 77%) rpoB 
S450L (8M > 90%), embB 
Q497R (8M = 88%) 
RIF 
(1M, 8M) 
EMB 
(8M) 
 2.2.1.1 
 
embB 
(D534D) 
 
2SRHZ/6HE 
 
         
Table 1. Emergence of genetic variants in de novo and intermediate emergence of MDR-TB isolates.  
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*ubiA – gene involved in M. tuberculosis cell wall biosynthesis and ethambutol resistance 
% - Percentage of reads with genetic variant compared to wild type reference. 
Bold sections highlight patient code, preexisting and emerging antibiotic resistant variants and phenotypes. 
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Table 2. Sub-lineages of initial (0M, 1M and 2M) and MDR-TB isolates from secondary infection. 
* only 19 SNPs difference between initial and MDR-TB isolate. 
  
Case ID  sub-lineage of initial M.tb isolate  (Lineage specific SNPs) sub-lineage of MDR-TB isolate (Month) 
Pt006 2.2.1 (Rv0697 (L268L)) 2.2.1 (2M) 
Pt007 2.2.1 (2M) 2.2.1 (5M) 
Pt008 2.2.1 2.2.1 (2M , 5M) 
Pt010 2.2.1 2.2.1 (1M , 2M,  5M) 
Pt012 4.8 (Rv3417c (D51D)) 2.2.1 (5M , 8M) 
Pt013 1.1.1.1 (Rv2907c(V113V)) 2.2.1 (12 M) 
Pt070 4.1.2 (Rv0798c (L172L)) 2.2.1 (5M) 
Pt093 4.5 (Rv1524(P344P)) 2.2.1 (12M) 
Pt151* 2.2.1 (1M) 2.2.1 (5M) 
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Figure 1 
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Figure 2 
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Figure 3 
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